5-[[(2S)-4-(cyclopropylsulfonyl)-2-morpholinyl]methoxy]-7-[4-(4-morpholinyl)phenyl]-pyrido[3,4-b]pyrazine | 1613258-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 5-[[(2S)-4-(cyclopropylsulfonyl)-2-morpholinyl]methoxy]-7-[4-(4-morpholinyl)phenyl]-pyrido[3,4-b]pyrazine
• 英文别名: (2S)-4-cyclopropylsulfonyl-2-[[7-(4-morpholin-4-ylphenyl)pyrido[3,4-b]pyrazin-5-yl]oxymethyl]morpholine
• CAS: 1613258-45-9
• 化学式: C₂₅H₂₉N₅O₅S
• 分子量: 511.602
• InChiKey: XRSMSWHMWGUMBT-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  115
• 氢给体数：
  0
• 氢受体数：
  10

文献信息

• Substituted Pyridopyrazines as Syk Inhibitors
  申请人：HUTCHISON MEDIPHARMA LIMITED

  公开号：US20160002221A1

  公开（公告）日：2016-01-07

  The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R 1 , R 2 , R 3 , L, m, p and W are as defined in the specification.

  本发明涉及式(I)的吡啶吡嗪化合物、其制药组合物和使用方法，其中R1、R2、R3、L、m、p和W如规范中所定义。
• SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS
  申请人：HUTCHISON MEDIPHARMA LIMITED

  公开号：US20150307491A1

  公开（公告）日：2015-10-29

  The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R 1 , R 2 , R 3 , L, m, p and W are as defined in the specification.

  本发明涉及式(I)的吡啶吡嗪化合物，其制药组合物和使用方法，其中R1、R2、R3、L、m、p和W如规范中所定义。
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180071303A1

  公开（公告）日：2018-03-15

  The application provides methods reducing the side effects of chemotherapy and radiotherapy, including, hematopoietic toxicity, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis and alopecia. The application provides a method for increasing the number of, neutrophil counts and platelet counts in a patient in need thereof, comprising administering an effective of an inhibitor of spleen tyrosine kinase (SYKi). The present application provides methods for treating myelosuppresive disorders by the administration of a SYKi. In certain embodiments, the myelosuppression is induced by the administration of one or more myelosuppressive agents, for example, anti-cancer drugs. The present application provides methods for treating AML/ALL in a patient with 11q23/MLL abnormalities comprising the step of administering an effective amount of a SYKi to said patient.